US010478574B2

(12) **United States Patent**
Djupesland et al.

(10) **Patent No.: US 10,478,574 B2**
(45) **Date of Patent: Nov. 19, 2019**

(54) **NASAL ADMINISTRATION**

(75) Inventors: **Per Gisle Djupesland**, Oslo (NO); **Roderick Peter Hafner**, Wiltshire (GB)

(73) Assignee: **OptiNose AS**, Oslo (NO)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 2846 days.

(21) Appl. No.: **12/161,466**

(22) PCT Filed: **Jan. 19, 2006**

(86) PCT No.: **PCT/GB2006/000182**
§ 371 (c)(1),
(2), (4) Date: **Feb. 1, 2011**

(87) PCT Pub. No.: **WO2007/083073**
PCT Pub. Date: **Jul. 26, 2007**

(65) **Prior Publication Data**

US 2011/0114087 A1 May 19, 2011

(51) **Int. Cl.**
H01M 4/86 (2006.01)
H01M 4/90 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC ***A61M 15/08*** (2013.01)

(58) **Field of Classification Search**
CPC A61M 15/002; A61M 15/0091; A61M 15/0098; A61M 15/08; A61M 11/02; A61M 11/08
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

39,678 A 8/1863 Russell
605,436 A 6/1898 Kellogg
(Continued)

FOREIGN PATENT DOCUMENTS

EP 0341967 11/1989
GB 2400565 10/2004
(Continued)

OTHER PUBLICATIONS

Mathison et al. (Nasal Route for Direct Delivery of Solutes to the Central Nervous System: Fact or Ficton? Journal of Drug Targeting, 1998. vol. 5 No. 6 pp. 415-441.*
(Continued)

Primary Examiner — Bhisma Mehta
Assistant Examiner — Matthew A Engel
(74) *Attorney, Agent, or Firm* — Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

(57) **ABSTRACT**

A delivery device for and method of providing for delivery of substance to the central nervous system (CNS) of a subject, the delivery device comprising: a nosepiece unit (**17**) for insertion into a nasal airway (**1**) of a subject and comprising an outlet unit (**21**) which includes a nozzle (**25**) for delivering substance into the nasal airway of the subject; and a substance supply unit which is operable to deliver a dose of substance to the nozzle: wherein the delivery device is configured such that at least 30% of the dose as initially deposited in the nasal airway is deposited in an upper posterior region of the nasal airway, thereby providing a CNS concentration of the substance, and hence CNS effect, which is significantly greater than that which would be predicted from a counterpart blood plasma concentration of the substance.

39 Claims, 11 Drawing Sheets